Novavax NVAX Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||
| Europe | $15.74M-83.4% | $95.05M-65.1% | $271.96M-67.1% | |
| Rest of North America | $575.67M+12,802% | $4.46M-66.7% | $13.39M-93.1% | |
| Rest of the world | $126.46M+110% | $60.19M-76.3% | $254.46M-55.9% | |
| United States | $405.61M-22.4% | $522.47M+17.7% | $443.89M+15.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Novavax break its business down?
- Novavax (NVAX) reports development, tech transfer, launch, and sales milestone payments by product across 5 parts — Adjuvant Products Thereafter, CIC Product-Related Development Milestones, CIC Product-Related Launch Milestones, First Four Adjuvant Products and Licensed COVID-19 products and royalty payments. Each is extracted from the segment footnotes and tracked over time.
- Where does Novavax's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Novavax's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
